reckon it could well become a dividend stock eventually, but not within the next 10 years or so. Cash earned in royalties and milestone payments in the 10 years ought to be reinvested in R&D to expand the base of the company so we're not dependent on just one drug. Exclusive rights expire over the next 7 -10 years, which allows other competitors into our space, eroding our revenues from only Trofinetide. There's many more neurological disorders and deteriorations that we need to be investigating to solve with our IP.
$20 party, page-50
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.23 |
Change
0.080(0.50%) |
Mkt cap ! $2.074B | |||
| Open | High | Low | Value | Volume |
| $16.39 | $16.57 | $16.04 | $10.33M | 637.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1336 | $16.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.30 | 3173 | 3 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |